Search PubMed⌕ Search

Biomedical subjects

L Blaha

Publications and source records attributed to L Blaha.

13 recordsLinked to original sources
PubMed1979

[Therapy of acute schizophrenic attacks. High dosage haloperidol therapy compared with a two component treatment].

In a controlled open study 18 patients were treated with high doses of haloperidol (Haldol-Janssen) from 50 to 100 mg daily and 15 patients with a combined therapy of 10 mg haloperidol and 150 to 300 mg levomepromazin (Neurocil). The high-dosed sample a significantly rapid decrease of the productive symptoms and improvement of the general condition were found. The medians of the rating scales and self-rating scales showed similar courses. Within the high-dosage group especially after the beginning of therapy, there was an unexpected significant increase in extrapyramidal signs (dyskinesias), which did not appear any more after starting with an initial dose of at least 50 mg Haldol-Janssen. Other side effects could not be found, the tolerance was good.

Anxiety↗
PubMed1979

A clinical view of clobazam.

1 The results so far published in the literature, together with our own results, show that in clobazam (Frisium) we have a daytime tranquilizer which is comparable to the newest benzodiazepine derivatives. 2 It is particularly indicated in disorders of the sleeping-waking rhythm, and sometimes also in psychovegetative disorders associated with epilepsy. 3. Its tranquillizing profile of action, the low incidence of side-effects and the absence of interactions with other drugs mean that its applications are varied, not only in neuropsychiatry but also in other medical disciplines. 4 The fact that therapeutic doses do not seem to impair driving ability to render patients incapable of carrying on their profession, means that it is suitable for the treatment of outpatients.

Anti-Anxiety Agents↗
PubMed1979

[Psychopathometric double blind study with nicergoline versus placebo in geriatric patients with slight transit syndromes].

A double-blind study was carried out on 56 geronto-psychiatric in-patients who suffered from cerebral metabolic and nutritional disturbances to prove the effectiveness of 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate (nicergoline, Sermion). After a washout-phase of eight days the patients in the verum group received 3 x 1 dragée at 10 mg for a period of 12 weeks. For methodical reasons only patients with slight transit syndromes and, of these, only the first four weeks of examination were included in the present analysis. Thus 8 verum and 9 placebo patients remain whose findings during the trial are recorded in three procedures of capacity and two procedures of self-assessment (syndrome short test, repeating figures and letters, reading letters; scale for general somatic discomfort, scale for vegetative functional disturbances). In the measuring procedures there is a tendency towards improvement under the treatment with nicergline compared with placebo during the first three weeks. But the present results are not sufficient to come to a clear decision on the effectiveness of nicergoline in patients with cerebrovascular insufficiency.

Aged↗
PubMed1978

[Psychopharmacologic drugs in the rehabilitation after myocardial infarct].

The specific use of psychotropic agents in myocardial infarction has become possible due to interdisciplinary cooperation. Especially the differentiated therapeutic application of benzodiazepine derivatives will take into better account the different psychopathologic states in the various phases. The medicamentous facilities are extended by using the central and peripheral effects of the beta-blockers. After a myocardial infarction there are various somatic and mental symptoms. This requires precise medical and psychological management with reference to a diagnostic and combined-therapeutic schedule of treatment. An intensive co-operation with all medical departments is a conditio sine qua non.

Adrenergic beta-Antagonists↗
PubMed1978

[Detecting psychopathological symptoms in psychopharmacological studies on the course of disease (author's transl)].

Rating scales and self-rating scales are still indispensable for the estimation of psychopathological symptoms and their variations in the course of treatment with psychopharmacologic agents. So significant progress can be recognized in measurment of intelligence, degree of severity of functional psychoses, states of cerebral defects and of endogenous depressions. The promising results of this experience encourage intensifying the development of such test instruments concerning non-psychotic psychic disturbances as well as schizophrenic psychoses.

Anxiety↗
PubMed1977

[Influence of oxprenolol on the affect level in an exam situation. A follow-up study under double-blind conditions (author's transl)].

In a double-blind study on student nurses the curves of three affectivity components and the pulse rate under exam conditions were observed. One group had received 1-(o-allyloxy-phenoxy)-3-isopropylamino-propan-2-ol hydrochloride (oxprenolol, Trasicor and the other group a placebo. In the examination stress the affectivity component "aggression" was particularly obvious. With placebo the states and actions of aggression were more extreme than in the oxprenolol group. It appeared that the severe affectivity inclinations resulted in a reduction of examination performance. Under oxprenolol, in accordance with recently published results, there was no decrease in performance under exam conditions. Quite the opposite: as it seems to curb extreme affectivity inclinations the decreases in performance connected with them are often prevented.

Affect↗